Sempra Energy vs Vir Biotechnology Inc. Common Stock — how do they compare? Sempra Energy trades at $82.38 (market cap $53.86B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Sempra Energy is far larger — about 29.9× Vir Biotechnology Inc. Common Stock's market cap, and Sempra Energy pays a 3.19% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sempra Energy for 9 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| SRE | VIR | |
|---|---|---|
Market Cap | $53.86B | $1.80B |
Volume | 2,605,713 | 1,782,836 |
Sector | Utilities | Health |
52-Week High | $99.75 | $11.78 |
52-Week Low | $76.90 | $5.12 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $90.50B | $1.36B |
Dividend Yield | 3.19% | — |
Signals from Pluang's Aura AI — not financial advice
Sempra Energy (SRE) trades at $82.37, up 0.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported strong Q2 2026 earnings that beat expectations, with a net income margin of 16.83% and robust cash flow from operations of $5.4 billion in 2026. Recent developments include a 20-year LNG supply agreement with Petrobras and the opening of SoCalGas' new headquarters, signaling growth initiatives.
The outlook for SRE is positive, supported by analyst consensus with an 80.77% buy rating and a price target of $97.25, implying significant upside. Key opportunities include EPS growth guidance of 7–9% and strategic investments in Texas and LNG. Risks involve high capital expenditures, regulatory exposure, and interest rate sensitivity. The stock's current valuation at a P/E of 23.88 requires continued execution to justify further gains.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Sempra is an energy infrastructure company with regulated utility and energy network businesses. Its operations include electric and gas utilities as well as energy infrastructure in North America.
Read more on SRE →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →